search
Back to results

A Multicenter Assessment of ALD403 in Chronic Migraine

Primary Purpose

Migraine Disorders

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
ALD403
Placebo
Sponsored by
Alder Biopharmaceuticals, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Migraine Disorders focused on measuring Migraine Disorders, ALD403

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of migraine at ≤ 35 years of age with history of chronic migraine ≥ 1 year
  • During the 28 day screening period, must have ≥ 15 headache days of which ≥ 8 days were assessed as migraine days with at least 5 migraine attacks as recorded in the eDiary
  • Headache eDiary was completed on at least 22 of the 28 days prior to randomization

Exclusion Criteria:

  • Confounding pain syndromes (e.g. fibromyalgia, chronic low back pain, complex regional pain syndrome) or any pain syndrome that requires regular analgesia
  • Psychiatric conditions that are uncontrolled and untreated, including conditions that are not controlled for a minimum of 6 months prior to screening.
  • History or diagnosis of complicated migraine (ICHD-III beta version, 2013), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, migraine with brainstem aura, sporadic and familial hemiplegic migraine
  • Unable to differentiate migraine from other headaches
  • Subject has received botulinum toxin for migraine or for any other medical/cosmetic reasons requiring injections in the head, face, or neck within 4 months prior to screening.
  • Have any clinically significant concurrent medical condition
  • Receipt of any monoclonal antibody treatment within 6 months of screening (within or outside a clinical trial)
  • Previously dosed with ALD403 or any monoclonal antibody targeting the CGRP pathway

Sites / Locations

  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Reserach Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

ALD403 Dose Level 1

ALD403 Dose Level 2

ALD403 Dose Level 3

ALD403 Dose Level 4

Placebo

Arm Description

ALD403 Dose Level 1 (IV)

ALD403 Dose Level 2 (IV)

ALD403 Dose Level 3 (IV)

ALD403 Dose Level 4 (IV)

Placebo (IV)

Outcomes

Primary Outcome Measures

75% Migraine Responder Rate
Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 12, as compared with baseline.

Secondary Outcome Measures

50% Migraine Responder Rate
Participants with an average reduction in migraine days of at least 50% over Weeks 1 to 12, as compared with baseline
50% Headache Responder Rate
Participants with an average reduction in headache days of at least 50% over Weeks 1 to 12, as compared with baseline
100% Headache Responder Rate
Participants with an average reduction in headache days of at least 100% over Weeks 1 to 12, as compared with baseline
100% Migraine Responder Rate
Participants with an average reduction in migraine days of at least 100% over Weeks 1 to 12, as compared with baseline
The Change From Baseline in Monthly Headache Days, Weeks 1-12
Monthly headache days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.
The Change From Baseline in Monthly Migraine Days, Weeks 1-12
Monthly migraine days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.
Change From Baseline in Percentage of Severe Migraines
The change from baseline in percentage of migraines that are classified as severe over Weeks 1-12
Change From Baseline in Percentage of Severe Headaches
The change from baseline in percentage of headaches that are classified as severe over Weeks 9-12
The Change From Baseline to Week 12 in HIT-6 Total Score
The HIT-6 measures the impact of headache on the participant's functional health and well-being in 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or fatigue; cognition; and emotional distress assessed over the prior 12-week period. The total possible scores range from 36 (no impact) to 78 (worst impact). A score of 60 or above is labeled as "severe".
Percent Change From Baseline in Headache Days
Monthly headache days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.
Percent Change From Baseline in Migraine Days
Monthly migraine days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.
Time to First Migraine After Dosing
The median number of days after dosing a participant had the next migraine using the eDiary as the recall method
Change From Baseline in Monthly Migraine Attacks, Weeks 1-12
The number of monthly migraine attacks summarized over Weeks 1-12. A migraine attack is defined as 1 continuously recorded migraine. One attack may result in multiple migraine days
Change From Baseline in Monthly Headache Episodes, Weeks 1-12
The number of monthly headache episodes as summarized over Weeks 1-12. A headache episode is defined as 1 continuously recorded headache. One episode may result in multiple headache days
Change From Baseline in Monthly Migraine Hours, Weeks 1-12
Migraine hours are the sum of the duration of migraines within 4 week intervals, and the average 4 week duration within 12 week intervals.
Change From Baseline in Monthly Headache Hours, Weeks 1-12
Headache hours are the sum of the duration of headaches within 4 week intervals, and the average 4 week duration within 12 week intervals.
Change From Baseline to Weeks 9-12 in Percentage of Migraines With Use of Acute Medication
The percent of migraines with acute medication usage. Participants with no migraines will be included with a rate of zero.
Change From Baseline to Weeks 9-12 in Percentage of Headaches With Use of Acute Medication
The percent of headaches with acute medication usage. Participants with no headaches will be included with a rate of zero.
Baseline and Change From Baseline in Short Form Health Survey (SF-36, Version 2.0) at Week 12
The SF-36 is a health survey containing 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks (range: 0=worst to 100=best). Increases from baseline indicate improvement.

Full Information

First Posted
October 20, 2014
Last Updated
March 30, 2020
Sponsor
Alder Biopharmaceuticals, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02275117
Brief Title
A Multicenter Assessment of ALD403 in Chronic Migraine
Official Title
A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With Chronic Migraine
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
October 2014 (undefined)
Primary Completion Date
March 2016 (Actual)
Study Completion Date
November 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alder Biopharmaceuticals, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Migraine Disorders
Keywords
Migraine Disorders, ALD403

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
665 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ALD403 Dose Level 1
Arm Type
Experimental
Arm Description
ALD403 Dose Level 1 (IV)
Arm Title
ALD403 Dose Level 2
Arm Type
Experimental
Arm Description
ALD403 Dose Level 2 (IV)
Arm Title
ALD403 Dose Level 3
Arm Type
Experimental
Arm Description
ALD403 Dose Level 3 (IV)
Arm Title
ALD403 Dose Level 4
Arm Type
Experimental
Arm Description
ALD403 Dose Level 4 (IV)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo (IV)
Intervention Type
Biological
Intervention Name(s)
ALD403
Other Intervention Name(s)
Eptinezumab-jjmr, Vyepti
Intervention Type
Biological
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
75% Migraine Responder Rate
Description
Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 12, as compared with baseline.
Time Frame
12 Weeks
Secondary Outcome Measure Information:
Title
50% Migraine Responder Rate
Description
Participants with an average reduction in migraine days of at least 50% over Weeks 1 to 12, as compared with baseline
Time Frame
Weeks 1-12
Title
50% Headache Responder Rate
Description
Participants with an average reduction in headache days of at least 50% over Weeks 1 to 12, as compared with baseline
Time Frame
Weeks 1-12
Title
100% Headache Responder Rate
Description
Participants with an average reduction in headache days of at least 100% over Weeks 1 to 12, as compared with baseline
Time Frame
Weeks 1-12
Title
100% Migraine Responder Rate
Description
Participants with an average reduction in migraine days of at least 100% over Weeks 1 to 12, as compared with baseline
Time Frame
Weeks 1-12
Title
The Change From Baseline in Monthly Headache Days, Weeks 1-12
Description
Monthly headache days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.
Time Frame
Weeks 1-12
Title
The Change From Baseline in Monthly Migraine Days, Weeks 1-12
Description
Monthly migraine days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.
Time Frame
Weeks 1-12
Title
Change From Baseline in Percentage of Severe Migraines
Description
The change from baseline in percentage of migraines that are classified as severe over Weeks 1-12
Time Frame
Weeks 1-12
Title
Change From Baseline in Percentage of Severe Headaches
Description
The change from baseline in percentage of headaches that are classified as severe over Weeks 9-12
Time Frame
Weeks 9-12
Title
The Change From Baseline to Week 12 in HIT-6 Total Score
Description
The HIT-6 measures the impact of headache on the participant's functional health and well-being in 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or fatigue; cognition; and emotional distress assessed over the prior 12-week period. The total possible scores range from 36 (no impact) to 78 (worst impact). A score of 60 or above is labeled as "severe".
Time Frame
Baseline to 12
Title
Percent Change From Baseline in Headache Days
Description
Monthly headache days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.
Time Frame
Weeks 1-12
Title
Percent Change From Baseline in Migraine Days
Description
Monthly migraine days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.
Time Frame
Weeks 1-12
Title
Time to First Migraine After Dosing
Description
The median number of days after dosing a participant had the next migraine using the eDiary as the recall method
Time Frame
Baseline to Week 49 (End of Study)
Title
Change From Baseline in Monthly Migraine Attacks, Weeks 1-12
Description
The number of monthly migraine attacks summarized over Weeks 1-12. A migraine attack is defined as 1 continuously recorded migraine. One attack may result in multiple migraine days
Time Frame
Weeks 1-12
Title
Change From Baseline in Monthly Headache Episodes, Weeks 1-12
Description
The number of monthly headache episodes as summarized over Weeks 1-12. A headache episode is defined as 1 continuously recorded headache. One episode may result in multiple headache days
Time Frame
Weeks 1-12
Title
Change From Baseline in Monthly Migraine Hours, Weeks 1-12
Description
Migraine hours are the sum of the duration of migraines within 4 week intervals, and the average 4 week duration within 12 week intervals.
Time Frame
Weeks 1-12
Title
Change From Baseline in Monthly Headache Hours, Weeks 1-12
Description
Headache hours are the sum of the duration of headaches within 4 week intervals, and the average 4 week duration within 12 week intervals.
Time Frame
Weeks 1-12
Title
Change From Baseline to Weeks 9-12 in Percentage of Migraines With Use of Acute Medication
Description
The percent of migraines with acute medication usage. Participants with no migraines will be included with a rate of zero.
Time Frame
Weeks 9-12
Title
Change From Baseline to Weeks 9-12 in Percentage of Headaches With Use of Acute Medication
Description
The percent of headaches with acute medication usage. Participants with no headaches will be included with a rate of zero.
Time Frame
Weeks 9-12
Title
Baseline and Change From Baseline in Short Form Health Survey (SF-36, Version 2.0) at Week 12
Description
The SF-36 is a health survey containing 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks (range: 0=worst to 100=best). Increases from baseline indicate improvement.
Time Frame
Baseline to Week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of migraine at ≤ 35 years of age with history of chronic migraine ≥ 1 year During the 28 day screening period, must have ≥ 15 headache days of which ≥ 8 days were assessed as migraine days with at least 5 migraine attacks as recorded in the eDiary Headache eDiary was completed on at least 22 of the 28 days prior to randomization Exclusion Criteria: Confounding pain syndromes (e.g. fibromyalgia, chronic low back pain, complex regional pain syndrome) or any pain syndrome that requires regular analgesia Psychiatric conditions that are uncontrolled and untreated, including conditions that are not controlled for a minimum of 6 months prior to screening. History or diagnosis of complicated migraine (ICHD-III beta version, 2013), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, migraine with brainstem aura, sporadic and familial hemiplegic migraine Unable to differentiate migraine from other headaches Subject has received botulinum toxin for migraine or for any other medical/cosmetic reasons requiring injections in the head, face, or neck within 4 months prior to screening. Have any clinically significant concurrent medical condition Receipt of any monoclonal antibody treatment within 6 months of screening (within or outside a clinical trial) Previously dosed with ALD403 or any monoclonal antibody targeting the CGRP pathway
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeff TL Smith, MD
Organizational Affiliation
Alder Biopharmaceuticals, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
Huntsville
State/Province
Alabama
ZIP/Postal Code
35801
Country
United States
Facility Name
Research Site
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36608
Country
United States
Facility Name
Research Site
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85027
Country
United States
Facility Name
Research Site
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85259
Country
United States
Facility Name
Research Site
City
Hot Springs
State/Province
Arkansas
ZIP/Postal Code
71901
Country
United States
Facility Name
Research Site
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72211
Country
United States
Facility Name
Research Site
City
Anaheim
State/Province
California
ZIP/Postal Code
92801
Country
United States
Facility Name
Research Site
City
Encino
State/Province
California
ZIP/Postal Code
91436
Country
United States
Facility Name
Reserach Site
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Facility Name
Research Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90036
Country
United States
Facility Name
Research Site
City
Oakland
State/Province
California
ZIP/Postal Code
94612
Country
United States
Facility Name
Research Site
City
San Diego
State/Province
California
ZIP/Postal Code
92108
Country
United States
Facility Name
Research Site
City
San Francisco
State/Province
California
ZIP/Postal Code
94102
Country
United States
Facility Name
Research Site
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Facility Name
Research Site
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
Facility Name
Research Site
City
Ventura
State/Province
California
ZIP/Postal Code
93003
Country
United States
Facility Name
Research Site
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80918
Country
United States
Facility Name
Research Site
City
Denver
State/Province
Colorado
ZIP/Postal Code
80210
Country
United States
Facility Name
Research Site
City
Stamford
State/Province
Connecticut
ZIP/Postal Code
06905
Country
United States
Facility Name
Research Site
City
Waterbury
State/Province
Connecticut
ZIP/Postal Code
06708
Country
United States
Facility Name
Research Site
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32607
Country
United States
Facility Name
Research Site
City
Hallandale Beach
State/Province
Florida
ZIP/Postal Code
33009
Country
United States
Facility Name
Research Site
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32256
Country
United States
Facility Name
Research Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33144
Country
United States
Facility Name
Research Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33173
Country
United States
Facility Name
Research Site
City
North Miami
State/Province
Florida
ZIP/Postal Code
33161
Country
United States
Facility Name
Research Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32801
Country
United States
Facility Name
Research Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
Research Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33606
Country
United States
Facility Name
Research Site
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30022
Country
United States
Facility Name
Research Site
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30342
Country
United States
Facility Name
Research Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60607
Country
United States
Facility Name
Research Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60640
Country
United States
Facility Name
Research Site
City
Evansville
State/Province
Illinois
ZIP/Postal Code
47714
Country
United States
Facility Name
Research Site
City
Normal
State/Province
Illinois
ZIP/Postal Code
61761
Country
United States
Facility Name
Research Site
City
Prairie Village
State/Province
Kansas
ZIP/Postal Code
66206
Country
United States
Facility Name
Research Site
City
Wichita
State/Province
Kansas
ZIP/Postal Code
67207
Country
United States
Facility Name
Research Site
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40207
Country
United States
Facility Name
Research Site
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70115
Country
United States
Facility Name
Research Site
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71105
Country
United States
Facility Name
Research Site
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
21310
Country
United States
Facility Name
Research Site
City
Brockton
State/Province
Massachusetts
ZIP/Postal Code
02301
Country
United States
Facility Name
Research Site
City
New Bedford
State/Province
Massachusetts
ZIP/Postal Code
02740
Country
United States
Facility Name
Research Site
City
Watertown
State/Province
Massachusetts
ZIP/Postal Code
02472
Country
United States
Facility Name
Research Site
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48104
Country
United States
Facility Name
Research Site
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63141
Country
United States
Facility Name
Research Site
City
Springfield
State/Province
Missouri
ZIP/Postal Code
65807
Country
United States
Facility Name
Research Site
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68134
Country
United States
Facility Name
Research Site
City
Princeton
State/Province
New Jersey
ZIP/Postal Code
08540
Country
United States
Facility Name
Research Site
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87102
Country
United States
Facility Name
Research Site
City
Albany
State/Province
New York
ZIP/Postal Code
12208
Country
United States
Facility Name
Research Site
City
Amherst
State/Province
New York
ZIP/Postal Code
14226
Country
United States
Facility Name
Research Site
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Facility Name
Research Site
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11235
Country
United States
Facility Name
Research Site
City
Endwell
State/Province
New York
ZIP/Postal Code
13760
Country
United States
Facility Name
Research Site
City
New York
State/Province
New York
ZIP/Postal Code
10019
Country
United States
Facility Name
Research Site
City
Rochester
State/Province
New York
ZIP/Postal Code
14609
Country
United States
Facility Name
Research Site
City
Cary
State/Province
North Carolina
ZIP/Postal Code
27518
Country
United States
Facility Name
Research Site
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
Facility Name
Research Site
City
Canton
State/Province
Ohio
ZIP/Postal Code
44718
Country
United States
Facility Name
Research Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45255
Country
United States
Facility Name
Research Site
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Name
Research Site
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43213
Country
United States
Facility Name
Research Site
City
Dayton
State/Province
Ohio
ZIP/Postal Code
45424
Country
United States
Facility Name
Research Site
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73116
Country
United States
Facility Name
Research Site
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Facility Name
Research Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Research Site
City
Willow Grove
State/Province
Pennsylvania
ZIP/Postal Code
19090
Country
United States
Facility Name
Research Site
City
Mount Pleasant
State/Province
South Carolina
ZIP/Postal Code
29464
Country
United States
Facility Name
Research Site
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37421
Country
United States
Facility Name
Research Site
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38119
Country
United States
Facility Name
Research Site
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
Facility Name
Research Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Facility Name
Research Site
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76104
Country
United States
Facility Name
Research Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77058
Country
United States
Facility Name
Research Site
City
Orem
State/Province
Utah
ZIP/Postal Code
84058
Country
United States
Facility Name
Research Site
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84109
Country
United States
Facility Name
Research Site
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23226
Country
United States
Facility Name
Research Site
City
Virginia Beach
State/Province
Virginia
ZIP/Postal Code
23454
Country
United States
Facility Name
Research Site
City
Bellevue
State/Province
Washington
ZIP/Postal Code
98007
Country
United States
Facility Name
Research Site
City
Seattle
State/Province
Washington
ZIP/Postal Code
98105
Country
United States
Facility Name
Research Site
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States
Facility Name
Research Site
City
Sydney
State/Province
New South Wales
ZIP/Postal Code
2031
Country
Australia
Facility Name
Research Site
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3004
Country
Australia
Facility Name
Research Site
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3050
Country
Australia
Facility Name
Research Site
City
Perth
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
Facility Name
Research Site
City
Tbilisi
ZIP/Postal Code
0112
Country
Georgia
Facility Name
Research Site
City
Tbilisi
ZIP/Postal Code
0160
Country
Georgia
Facility Name
Research Site
City
Tbilisi
ZIP/Postal Code
0186
Country
Georgia
Facility Name
Research Site
City
Auckland
ZIP/Postal Code
8963
Country
New Zealand
Facility Name
Research Site
City
Christchurch
ZIP/Postal Code
2856
Country
New Zealand
Facility Name
Research Site
City
Hamilton
ZIP/Postal Code
3204
Country
New Zealand

12. IPD Sharing Statement

Citations:
PubMed Identifier
34823467
Citation
Smith TR, Spierings ELH, Cady R, Hirman J, Ettrup A, Shen V. Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies. J Headache Pain. 2021 Nov 25;22(1):143. doi: 10.1186/s10194-021-01360-1.
Results Reference
derived
PubMed Identifier
33781209
Citation
Smith TR, Spierings ELH, Cady R, Hirman J, Schaeffler B, Shen V, Sperling B, Brevig T, Josiassen MK, Brunner E, Honeywell L, Mehta L. Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain. 2021 Mar 30;22(1):16. doi: 10.1186/s10194-021-01227-5. Erratum In: J Headache Pain. 2021 May 25;22(1):46.
Results Reference
derived
PubMed Identifier
31234642
Citation
Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Cady R, Smith J. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia. 2019 Aug;39(9):1075-1085. doi: 10.1177/0333102419858355. Epub 2019 Jun 24.
Results Reference
derived
Links:
URL
http://www.migrainestudynow.com/
Description
Related Info

Learn more about this trial

A Multicenter Assessment of ALD403 in Chronic Migraine

We'll reach out to this number within 24 hrs